At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 54 enrolled
Drug / intervention
Efavirenz +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-"Nearly Naive" Participants
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·interventional·Posted Mar 5, 2007·Updated Oct 12, 2018
In Brief
A Phase 4 clinical trial evaluating Efavirenz and Emtricitabine/Tenofovir disoproxil fumarate for HIV Infections. Completed, enrolled 54 participants across 9 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine if pregnancy-limited, short-term combination HIV treatment regimens -- which were used solely for the prevention of mother to child transmission of HIV and discontinued postpartum -- decreases the effectiveness of a standard initial regimen of anti-HIV drugs when subsequent treatment is needed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesBrazil, Peru, United States
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionJul 2010
Study CompletionDec 2010
TodayJul 2026
First PostedMar 5, 2007
Enrollment StartMay 1, 2007
Primary CompletionJul 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.3 years ago
Interventions
Efavirenzdrug
600-mg tablet taken orally daily
Emtricitabine/Tenofovir disoproxil fumaratedrug
200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily